Screening for Asymptomatic HSV-2 Infection

Recommended Testing Approach

• The American College of Physicians and other medical organizations recommend type-specific serological testing using glycoprotein G-based assays for screening asymptomatic individuals for HSV-2 infection, with high sensitivity and specificity (approximately 97% and 98%, respectively) for detecting HSV-2 antibodies 1, 2
• Venous blood samples should be collected for serological testing, and nucleic acid amplification tests (NAATs) are not appropriate for screening asymptomatic individuals without lesions 1, 2, 3

Target Populations for Screening

• The US Preventive Services Task Force and the European Centre for Disease Prevention and Control recommend type-specific HSV-2 serology for high-risk groups, including pregnant women at risk of acquiring HSV infection close to delivery, men who have sex with men, people who are HIV positive, and sexual partners of individuals with known genital herpes 1, 2, 3, 4
• Widespread screening for HSV-2 antibodies in the general population is discouraged by the US Preventive Services Task Force and other organizations 1, 2, 4

Interpretation of Results

• A positive HSV-2 IgG antibody test indicates past exposure and ongoing latent infection with HSV-2, with antibodies developing within several weeks after infection and persisting indefinitely 4
• The test cannot distinguish between recent and long-standing infections, and false positives are more common in individuals with HSV-1 infection, especially with low index values 4

Confirmatory Testing

• For low positive results (index value <3.0), confirmation with a second test using a different glycoprotein G antigen is recommended by the European Centre for Disease Prevention and Control and other organizations 4
• Western blot/immunoblot is considered the gold standard for HSV serologic testing but has limited availability 4

Clinical Pitfalls and Considerations

• A negative result within 12 weeks of potential exposure may represent the "window period" and should be repeated after 12 weeks if recent acquisition is suspected, according to the US Centers for Disease Control and Prevention and other organizations 4
• Serological tests alone cannot determine the etiology of a presenting genital lesion with certainty, and IgM testing is not recommended for screening as approximately one-third of patients with recurrent genital herpes caused by HSV-2 have IgM responses 2, 3

Post-Test Management

• Patients with positive HSV-2 serology should be counseled about the natural history of the disease, potential for recurrent episodes, asymptomatic viral shedding, and sexual transmission risk, according to the American College of Physicians and other organizations 1
• Treatment options include episodic therapy for outbreaks or suppressive therapy to reduce recurrences and transmission risk, as recommended by the European Centre for Disease Prevention and Control and other organizations 4

Laboratory Testing for Genital Herpes Without Active Lesions

Introduction to Genital Herpes Testing

• The American College of Physicians recommends type-specific serologic antibody testing for diagnosing genital herpes in patients without current lesions, as viral detection tests should never be performed without active lesions 5

The Critical Distinction: Which Test for Which Situation

• Viral detection methods, such as PCR/NAAT or culture, should not be obtained in the absence of genital ulcers because HSV shedding is intermittent, making swabs obtained without lesions insensitive and unreliable 5
• The sensitivity of HSV-2 serologic testing is approximately 92%, with specificity around 97-98% when using glycoprotein G-based assays 5

Important Caveats About Serologic Testing

• A negative serologic test can occur if testing is performed too early after infection, as antibodies may take up to 12 weeks to develop, representing a true false-negative during the "window period" 5
• Index values of 1.1-2.9 have only 39.8% specificity, meaning 60% are false positives, while index values ≥3.0 have 78.6% specificity, still resulting in 21% false positives 5
• Patients with HSV-1 infection are more likely to have false-positive HSV-2 tests with low index values 5
• HSV-1 serologic assays lack sensitivity, with only 70.2% sensitivity in one study, resulting in false-negative diagnoses 5

Epidemiology of Genital Herpes

• Most genital herpes (80-90%) progresses subclinically, and many patients have asymptomatic viral shedding without recognizing symptoms 6, 7, 8, 9

Screening for HSV-1 and HSV-2 IgG Antibodies in Asymptomatic Patients

Recommendations

• The U.S. Preventive Services Task Force recommends against routine serologic screening for HSV-2 infection in asymptomatic adolescents and adults with a Grade D recommendation, meaning the harms outweigh the benefits, for the general population 10
• The American family physician recommends against routine screening for HSV-1 and HSV-2 IgG antibodies in asymptomatic patients, as it does not improve health outcomes 10

Exceptions to Screening Recommendations

• Type-specific HSV-2 serology using glycoprotein G-based assays may be considered in pregnant women at risk of acquiring HSV infection close to delivery, as recommended by the Eurosurveillance guideline 11
• Type-specific HSV-2 serology using glycoprotein G-based assays may be considered in men who have sex with men, as recommended by the Eurosurveillance guideline 11
• Type-specific HSV-2 serology using glycoprotein G-based assays may be considered in people who are HIV-positive, as recommended by the Eurosurveillance and MMWR Recommendations and Reports guidelines 11, 12

Asymptomatic HSV Infection

Epidemiology and Transmission

• The vast majority of HSV-infected individuals (approximately 91% of HSV-2 seropositive persons) remain unaware of their infection because they either never develop recognizable symptoms or have such mild manifestations that they don't recognize them as herpes 13, 14, 15
• Only 9% of HSV-2-seropositive persons report having genital herpes, despite having antibodies that confirm infection 13, 14, 15
• Most genital herpes infections are transmitted by persons who are unaware they have the infection or are asymptomatic when transmission occurs 13, 14, 15
• Don't assume absence of outbreaks means absence of infection or transmission risk—asymptomatic shedding is common and responsible for most transmission 13

Diagnosis and Management

• Suppressive antiviral therapy reduces, but does not eliminate, subclinical viral shedding, confirming that viral replication occurs without symptoms 14, 15
• Don't perform HSV molecular assays in the absence of genital ulcers—due to intermittent shedding, swabs without lesions are insensitive 16
• Don't rely on patient recall of symptoms alone—most infected individuals don't recognize mild or atypical presentations 13

IVIG Indications and Their Influence on HSV Serology

Indications for Intravenous Immunoglobulin (IVIG)

• IVIG replacement therapy is recommended for patients whose serum IgG concentration is below 400 mg/dL. 17
• IVIG is indicated for individuals who have experienced two or more severe recurrent infections caused by encapsulated bacteria, irrespective of their measured IgG level. 17
• IVIG is employed in cases of life‑threatening infections or documented bacterial infections that fail to improve with appropriate antibiotic therapy. 17

Effect of IVIG on Herpes Simplex Virus (HSV) Serologic Testing

• In patients with hypogammaglobulinemia, routine IgG and IgM serology for past viral infections (including HSV) may be performed, but results must be interpreted with caution because administered IVIG can alter antibody concentrations and lead to misleading findings. 17
• Hypogammaglobulinemic patients are at risk for false‑negative HSV serologic results due to an impaired ability to generate adequate antibody responses despite infection. 17

HSV Screening Recommendations for Asymptomatic Individuals

General Recommendation Against Routine Screening

• The United States Preventive Services Task Force (USPSTF) issues a Grade D recommendation that routine serologic screening for HSV‑2 in asymptomatic adolescents and adults should not be performed because the harms outweigh any potential benefit. 18
• Routine serologic testing for both HSV‑1 and HSV‑2 in asymptomatic patients who have no risk factors (e.g., few lifetime sexual partners, no known HSV‑2‑positive partners, no genital symptoms) is not recommended. 19
• Screening pregnant women who lack specific risk factors for HSV acquisition near delivery is also discouraged. 20

Rationale: Test Performance Limitations in Low‑Risk Populations

• Commercial HSV serologic assays show poor specificity in low‑prevalence groups, leading to a high proportion of false‑positive results. 18
• Individuals with prior HSV‑1 infection are especially prone to false‑positive HSV‑2 serology when low index values are reported. 20

High‑Risk Situations Where Testing May Be Considered

• People living with HIV who are unaware of their HSV‑2 status and are considering suppressive antiviral therapy to reduce transmission should be offered HSV‑2 serologic testing. 21
• Sexual partners of persons with confirmed genital HSV‑2 infection have an elevated epidemiologic risk and should be screened. 19
• Patients presenting with genital symptoms (classic or atypical) suggestive of herpes should undergo HSV‑2 serology to aid diagnosis. 18
• Individuals who have been told they have genital herpes but lack a virologic confirmation have a high pre‑test probability and should receive HSV‑2 serologic testing. 20

Interpretation of Serologic Index Values

• An index value ≥ 3.0 is generally sufficient to diagnose HSV‑2 infection without additional confirmatory testing, although occasional false‑positives have been reported at values > 3.5. 18

Summary Statement

• In asymptomatic patients without identifiable risk factors, HSV serologic testing should be avoided because of poor test performance, lack of clinical benefit, and potential psychological harm. 19
• Testing should be reserved for symptomatic individuals or clearly defined high‑risk groups where a positive result can lead to meaningful clinical interventions (e.g., antiviral suppression, counseling, obstetric management). 20